Annual EBITDA
-$28.90 M
-$7.91 M-37.72%
June 1, 2024
Summary
- As of March 1, 2025, RADX annual EBITDA is -$28.90 million, with the most recent change of -$7.91 million (-37.72%) on June 1, 2024.
- During the last 3 years, RADX annual EBITDA has fallen by -$15.87 million (-121.87%).
- RADX annual EBITDA is now -121.87% below its all-time high of -$13.03 million, reached on June 1, 2022.
Performance
RADX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RADX EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -37.7% | - | - |
3 y3 years | -121.9% | - | - |
5 y5 years | -121.9% | - | - |
RADX EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -121.9% | at low | ||||
5 y | 5-year | -121.9% | at low | ||||
alltime | all time | -121.9% | at low |
Radiopharm Theranostics Limited EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2024 | -$28.90 M(+37.7%) | - | - |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2023 | -$20.99 M(+61.1%) | - | - |
Jun 2022 | -$13.03 M | - | - |
FAQ
- What is Radiopharm Theranostics Limited annual EBITDA?
- What is the all time high annual EBITDA for Radiopharm Theranostics Limited?
- What is Radiopharm Theranostics Limited annual EBITDA year-on-year change?
What is Radiopharm Theranostics Limited annual EBITDA?
The current annual EBITDA of RADX is -$28.90 M
What is the all time high annual EBITDA for Radiopharm Theranostics Limited?
Radiopharm Theranostics Limited all-time high annual EBITDA is -$13.03 M
What is Radiopharm Theranostics Limited annual EBITDA year-on-year change?
Over the past year, RADX annual EBITDA has changed by -$7.91 M (-37.72%)